Daniel J. Becker - 21 Jun 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Charles N. York II, as Attorney-in-Fact for Reporting Person
Issuer symbol
DAWN
Transactions as of
21 Jun 2022
Net transactions value
$0
Form type
4
Filing time
23 Jun 2022, 18:08:36 UTC
Previous filing
01 Jun 2021
Next filing
04 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Director Stock Option (Right to buy Common Stock) Award $0 +28,700 $0.000000 28,700 21 Jun 2022 Common Stock 28,700 $16.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/12th of the total shares on each monthly anniversary, beginning on July 21, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.